Zachary Zimmerman, Forge Therapeutics CEO

Forge spin­off Black­smith Med­i­cines merges back in­to com­pa­ny two years af­ter launch, but de­tails are slim

Black­smith Med­i­cines and Forge Ther­a­peu­tics an­nounced Mon­day that the com­pa­nies are merg­ing on­ly a year af­ter Black­smith launched as a spin­out of Forge, but there is lit­tle in­for­ma­tion pro­vid­ed on the uni­fi­ca­tion.

The fo­cus will be on in­fec­tion and on­col­o­gy re­search to de­vel­op drugs to tar­get met­al­loen­zymes, or en­zyme pro­teins that con­tain a met­al ion like mag­ne­sium, zinc, iron, man­ganese, cal­ci­um, cobalt or cop­per and per­form a wide range of func­tions in the body from mi­to­chon­dr­i­al func­tion to ni­tric ox­ide pro­duc­tion. Met­al­loen­zymes ac­count for over 30% of all known en­zymes across all species.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.